dc.contributor.author |
Bursacovschi, Natalia |
|
dc.date.accessioned |
2022-02-18T10:07:54Z |
|
dc.date.available |
2022-02-18T10:07:54Z |
|
dc.date.issued |
2010 |
|
dc.identifier.citation |
BURSACOVSCHI, Natalia. Pulmonary arterial hypertension in scleroderma. In: MedEspera: the 3rd Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2010, p. 44. |
en_US |
dc.identifier.uri |
http://repository.usmf.md/handle/20.500.12710/20211 |
|
dc.description.abstract |
Systemic sclerosis (SSc) is a rare chronic disease of unknown cause characterized by diffuse
fibrosis and degenerative changes in the skin and internal organs. It can cause serious complications
in the lungs in two major ways: the pulmonary fibrosis and pulmonary hypertension (PAH). Owing to
the fact that lung damage in SSc has a high incidence (70 % in the necropsy studies) and represents
the leading cause of death in scleroderma patients, it is required an early systemic evaluation of lung
complications in these patients. The objective was to study the particularities of lung complications in
patients with SSc. Material and methods This study is based on the surveying of 12 patients with the
SSc, aged between 28 and 68 years old, the majority of the patients being females. The diagnosis was
established on the bases of the clinical presentation, the laboratory data and the instrumental
examination: hemoleucogram, immunological tests (Anti-Scl 70 antibody, Anticentromere antibody),
ECG, echocardiography, spirography, chest X-ray, CT of the chest, pulse-oximetry. Results and
discussions The lung complications were determined in a big number of patients 83.3 %. PAH was
diagnosed in 4 patients: 1 case of severe isolated PAH in a patient with limited form of SSc, and 3
cases of light PAH associated with pulmonary fibrosis. Pulmonary fibrosis without PAH was
determined in a half of examined patients. Cor pulmonale was revealed in 2 patients, both of them
with PAH. The symptoms of lung damage were non-specific and consisted of shortness of breath
from an activity (at 8 patients from 10) and dry cough (at 5 patients from 10). In order to treat the
severe PAH was administrated a phosphodiesterase 5 inhibitor (Sildenafil) and a calcium channel
blocker (Verapamil) with a good clinical and hemodynamic response. Conclusions: 1. Both the
diffuse and the limited subsets of scleroderma patient may develop PAH, but it is more common in
patients with limited scleroderma. 2. Symptoms that might indicate PAH are non-specific. 3.
Echocardiography is recommended in the annual evaluation of all sclerodermic patients. 4. New
effective treatments may improve quality of life and improve long-term outcome. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Nicolae Testemitanu State Medical and Pharmaceutical University |
en_US |
dc.relation.ispartof |
MedEspera: The 3rd International Medical Congress for Students and Young Doctors, May 19-21, 2010, Chisinau, Republic of Moldova |
en_US |
dc.title |
Pulmonary arterial hypertension in scleroderma |
en_US |
dc.type |
Other |
en_US |